These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 1895153)

  • 1. Determination of erythrocyte-bound acetylcholinesterase activity for monitoring pyridostigmine therapy in myasthenia gravis.
    Henze T; Nenner M; Michaelis HC
    J Neurol; 1991 Jul; 238(4):225-9. PubMed ID: 1895153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of myasthenia gravis with cholinesterase inhibitors--principles and pharmacologic monitoring].
    Henze T
    Fortschr Neurol Psychiatr; 1996 Mar; 64(3):110-21. PubMed ID: 8900891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.
    Milner-Brown HS; Mellenthin M; Sharma ML; Miller RG
    Neurology; 1987 May; 37(5):800-3. PubMed ID: 3574680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of myasthenia gravis: focus on pyridostigmine.
    Maggi L; Mantegazza R
    Clin Drug Investig; 2011 Oct; 31(10):691-701. PubMed ID: 21815707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma pyridostigmine levels in patients with myasthenia gravis.
    Calvey TN; Chan K
    Clin Pharmacol Ther; 1977 Feb; 21(2):187-93. PubMed ID: 837637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma concentration of pyridostigmine and effects in myastenia gravis.
    Chan K; Calvey TN
    Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.
    Davison SC; Hyman NM; Dehghan A; Chan K
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1141-5. PubMed ID: 7334410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful desensitization protocol for pyridostigmine in a 12 year old patient with myasthenia gravis.
    Kaplan F; Topal E
    Turk J Pediatr; 2023; 65(2):326-329. PubMed ID: 37114698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
    Tripathi M; Kaushik S; Dubey P
    J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma pyridostigmine levels in myasthenia gravis.
    White MC; De Silva P; Havard CW
    Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis.
    Goti P; Spinelli A; Marconi G; Duranti R; Gigliotti F; Pizzi A; Scano G
    Thorax; 1995 Oct; 50(10):1080-6. PubMed ID: 7491557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of echothiophate in myasthenia gravis.
    Foldes FF; Foldes VM; McNall PG
    Clin Pharmacol Ther; 1966; 7(5):620-30. PubMed ID: 5957167
    [No Abstract]   [Full Text] [Related]  

  • 13. Malabsorption of pyridostigmine in patients with myasthenia gravis.
    Cohan SL; Dretchen KL; Neal A
    Neurology; 1977 Mar; 27(3):299-301. PubMed ID: 557769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
    Schumm F; Gaertner HJ; Wiatr G; Dichgans J
    Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady state kinetics of pyridostigmine in myasthenia gravis.
    Sørensen PS; Flachs H; Friis ML; Hvidberg EF; Paulson OB
    Neurology; 1984 Aug; 34(8):1020-4. PubMed ID: 6540381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial.
    Sieb JP; Köhler W
    Clin Neurol Neurosurg; 2010 Nov; 112(9):781-4. PubMed ID: 20663605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials.
    Lorenzoni PJ; Kay CSK; Ducci RD; Fustes OJH; Werneck LC; Scola RH
    Arq Neuropsiquiatr; 2020 Mar; 78(3):179-181. PubMed ID: 32215460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridostigmine levels in myasthenia gravis.
    Kornfeld P; Mittag T; Genkins G; Papatestas AE; Horowitz SH
    Neurology; 1977 Nov; 27(11):1099. PubMed ID: 563008
    [No Abstract]   [Full Text] [Related]  

  • 19. Mivacurium chloride and myasthenia gravis.
    Seigne RD; Scott RP
    Br J Anaesth; 1994 Apr; 72(4):468-9. PubMed ID: 8155454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis.
    Punga AR; Sawada M; Stålberg EV
    Muscle Nerve; 2008 Mar; 37(3):300-7. PubMed ID: 18069667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.